Federated Hermes
ADPT icon

Federated Hermes’s Adaptive Biotechnologies ADPT Stock Holding History

Federated Hermes’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-632
Closed -$9.46K – 2066
2025
Q3 		$9.46K Sell
632
-1,048
-62% -$12.8K ﹤0.01% 1887
2025
Q2 		$19.6K Sell
1,680
-1,378
-45% -$12.5K ﹤0.01% 1715
2025
Q1 		$22.7K Sell
3,058
-4,912
-62% -$37.8K ﹤0.01% 1711
2024
Q4 		$47.8K Sell
7,970
-3,289
-29% -$18.1K ﹤0.01% 1677
2024
Q3 		$57.6K Sell
11,259
-46,013
-80% -$200K ﹤0.01% 1631
2024
Q2 		$207K Sell
57,272
-1,244,445
-96% -$3.95M ﹤0.01% 1470
2024
Q1 		$4.18M Buy
1,301,717
+89,057
+7% +$345K 0.01% 768
2023
Q4 		$5.94M Sell
1,212,660
-172,547
-12% -$787K 0.01% 674
2023
Q3 		$7.55M Buy
1,385,207
+272,720
+25% +$1.8M 0.02% 598
2023
Q2 		$7.46M Sell
1,112,487
-63,569
-5% -$473K 0.02% 606
2023
Q1 		$10.4M Sell
1,176,056
-231,130
-16% -$2.04M 0.03% 536
2022
Q4 		$10.8M Buy
1,407,186
+5,847
+0.4% +$45.5K 0.03% 522
2022
Q3 		$9.98M Buy
1,401,339
+3,806
+0.3% +$35.8K 0.03% 531
2022
Q2 		$11.3M Buy
1,397,533
+841,334
+151% +$7.4M 0.03% 525
2022
Q1 		$7.72M Buy
+556,199
New +$8.74M 0.02% 672
2021
Q2 		– Sell
-42,000
Closed -$1.69M – 2195
2021
Q1 		$1.69M Sell
42,000
-18,088
-30% -$979K ﹤0.01% 1168
2020
Q4 		$3.55M Buy
60,088
+18,088
+43% +$933K 0.01% 901
2020
Q3 		$2.04M Hold
42,000
– – ﹤0.01% 979
2020
Q2 		$2.03M Sell
42,000
-14,296
-25% -$521K 0.01% 993
2020
Q1 		$1.56M Buy
56,296
+9,061
+19% +$253K ﹤0.01% 968
2019
Q4 		$1.41M Buy
47,235
+5,235
+12% +$150K ﹤0.01% 1141
2019
Q3 		$1.3M Sell
42,000
-33,000
-44% -$1.35M ﹤0.01% 1190
2019
Q2 		$3.62M Buy
+75,000
New +$3.32M 0.01% 878

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Federated Hermes's ADPT Position: Q4 2025 in Review

Federated Hermes sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 632 shares — an estimated $9.46K sold.

Federated Hermes first reported a position in ADPT in Q2 2019 and held it in 23 quarters. The position peaked at $11.3M in Q2 2022. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

  • Federated Hermes reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Federated Hermes sold 632 Adaptive Biotechnologies shares in Q4 2025, an estimated $9.46K.
  • Federated Hermes first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 23 quarters.
  • Federated Hermes's Adaptive Biotechnologies position peaked at $11.3M in Q2 2022.
  • 283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Federated Hermes's 13F filing for Q4 2025, filed 12 Feb 2026.